Donal O'Connor's most recent trade in Theravance Biopharma Inc was a trade of 24,258 Share Option (Right to Buy) done . Disclosure was reported to the exchange on May 19, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Theravance Biopharma Inc | Donal O'Connor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2025 | 24,258 | 24,258 | - | - | Share Option (Right to Buy) | |
| Theravance Biopharma Inc | Donal O'Connor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2025 | 10,649 | 74,204 (0%) | 0% | 0 | Ordinary Shares | |
| Perrigo Company plc | Donal O'Connor | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.01 per share. | 14 May 2025 | 9,904 | 35,391 (0%) | 0% | 26.0 | 257,603 | Ordinary Shares |
| Perrigo Company plc | Donal O'Connor | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2025 | 9,904 | 0 | - | - | Restricted Stock Units | |
| Perrigo Company plc | Donal O'Connor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2025 | 7,305 | 7,305 | - | - | Restricted Stock Units | |
| Perrigo Company plc | Donal O'Connor | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.01 per share. | 14 May 2025 | 4,754 | 30,637 (0%) | 0% | 26.0 | 123,652 | Ordinary Shares |
| Perrigo Company plc | Donal O'Connor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2024 | 9,904 | 9,904 | - | - | Restricted Stock Units | |
| Perrigo Company plc | Donal O'Connor | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2024 | 8,764 | 0 | - | - | Restricted Stock Units | |
| Perrigo Company plc | Donal O'Connor | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.22 per share. | 14 May 2024 | 8,764 | 29,694 (0%) | 0% | 30.2 | 264,848 | Ordinary Shares |
| Perrigo Company plc | Donal O'Connor | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 30.22 per share. | 14 May 2024 | 4,207 | 25,487 (0%) | 0% | 30.2 | 127,136 | Ordinary Shares |
| Theravance Biopharma Inc | Donal O'Connor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2024 | 23,576 | 23,576 | - | - | Share Option (Right to Buy) | |
| Theravance Biopharma Inc | Donal O'Connor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2024 | 10,537 | 63,555 (0%) | 0% | 0 | Ordinary Shares | |
| Perrigo Company plc | Donal O'Connor | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2023 | 7,778 | 0 | - | - | Restricted Stock Units | |
| Perrigo Company plc | Donal O'Connor | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 32.86 per share. | 17 May 2023 | 7,778 | 24,664 (0%) | 0% | 32.9 | 255,585 | Ordinary Shares |
| Perrigo Company plc | Donal O'Connor | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.86 per share. | 17 May 2023 | 3,734 | 20,930 (0%) | 0% | 32.9 | 122,699 | Ordinary Shares |
| Perrigo Company plc | Donal O'Connor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2023 | 8,764 | 8,764 | - | - | Restricted Stock Units | |
| Theravance Biopharma Inc | Donal O'Connor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2023 | 22,044 | 22,044 | - | - | Share Option (Right to Buy) | |
| Theravance Biopharma Inc | Donal O'Connor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2023 | 9,132 | 53,018 (0%) | 0% | 0 | Ordinary Shares | |
| Theravance Biopharma Inc | Donal O'Connor | Director | Sale or transfer of securities back to the company at price $ 10.50 per share. | 22 Nov 2022 | 10,000 | 43,886 (0%) | 0% | 10.5 | 105,000 | Ordinary Shares |
| Perrigo Company plc | Donal O'Connor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2022 | 7,778 | 7,778 | - | - | Restricted Stock Units | |
| Perrigo Company plc | Donal O'Connor | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 May 2022 | 6,599 | 0 | - | - | Restricted Stock Units | |
| Perrigo Company plc | Donal O'Connor | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 38.57 per share. | 17 May 2022 | 6,599 | 20,054 (0%) | 0% | 38.6 | 254,523 | Ordinary Shares |
| Perrigo Company plc | Donal O'Connor | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 38.57 per share. | 17 May 2022 | 3,168 | 16,886 (0%) | 0% | 38.6 | 122,190 | Ordinary Shares |
| Theravance Biopharma Inc | Donal O'Connor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Apr 2022 | 28,000 | 28,000 | - | - | Share Option (Right to Buy) | |
| Theravance Biopharma Inc | Donal O'Connor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Apr 2022 | 9,852 | 53,886 (0%) | 0% | 0 | Ordinary Shares | |
| Perrigo Company plc | Donal O'Connor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2021 | 6,599 | 6,599 | - | - | Restricted Stock Units | |
| Perrigo Company plc | Donal O'Connor | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2021 | 5,804 | 0 | - | - | Restricted Stock Units | |
| Perrigo Company plc | Donal O'Connor | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 42.96 per share. | 07 May 2021 | 5,804 | 16,241 (0%) | 0% | 43.0 | 249,340 | Ordinary Shares |
| Perrigo Company plc | Donal O'Connor | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.96 per share. | 07 May 2021 | 2,786 | 13,455 (0%) | 0% | 43.0 | 119,687 | Ordinary Shares |
| Theravance Biopharma Inc | Donal O'Connor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2021 | 9,828 | 44,034 (0%) | 0% | 0 | Ordinary Shares | |
| Theravance Biopharma Inc | Donal O'Connor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2021 | 6,000 | 6,000 | - | - | Share Option (Right to Buy) |